Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
RTTNews
|
964 days ago

(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
606 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
862 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
889 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
961 days ago
European Shares Rise On Trade Deal Hopes
European stocks opened higher on Wednesday amid expectations of a potential trade deal with the United States.
RTTNews
|
12 minutes ago
Asian Shares Mixed As China's Factory Activity Contracts
Asian stocks ended mixed on Wednesday after a slew of U.S. companies suspended or tweaked their full year guidance and regional factory activity data disappointed.
RTTNews
|
48 minutes ago
German Economy Recovers On Spending, Investment
The German economy recovered in the first quarter driven by higher private consumption and investment, flash data from Destatis revealed on Wednesday. Gross domestic product grew 0.2 percent sequentially, offsetting the 0.2 percent fall in the preceding quarter. The rate also matched economists' expectations. The calendar-adjusted GDP posted an annual fall of 0.2 percent.
RTTNews
|
56 minutes ago
Canadian Dollar Climbs Against Most Majors
The Canadian dollar strengthened against most major currencies in the Asian session on Wednesday.
RTTNews
|
1h 51min ago